과민성 방광 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2025-2032년)

Global Overactive Bladder Treatment Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 3.67 billion in 2024 to USD 5.34 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The Global Overactive Bladder (OAB) Treatment Market is experiencing robust growth driven by a rising aging population, which is more susceptible to bladder dysfunction due to age-related changes. This demographic shift correlates with higher occurrences of urinary urgency and frequency, escalating the demand for effective treatment options. Alongside this, continuous innovation in therapeutic solutions is reshaping the market. Traditional anticholinergic medications have seen reduced patient compliance due to side effects, but advancements such as B3-adrenoceptor agonists, Botox injections, and neuromodulation therapies offer safer and more tolerable alternatives. These developments not only enhance clinical outcomes but also foster greater patient and physician adoption, positioning improved efficacy and minimized side effects as pivotal factors in the ongoing expansion of the OAB treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Overactive Bladder Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Overactive Bladder Treatment Market Segments Analysis

Global Overactive Bladder Treatment Market is segmented by Treatment Type, Route of Administration, Distribution Channel and region. Based on Treatment Type, the market is segmented into Anticholinergics, Beta-3 Adrenergic Agonists, Neuromodulation, Botulinum Toxin Injections and Behavioral Therapies. Based on Route of Administration, the market is segmented into Oral, Intravesical, Transdermal and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Overactive Bladder Treatment Market

The expansion of the global overactive bladder treatment market is significantly influenced by the growing aging population worldwide. As individuals age, there is a natural decline in bladder muscle functionality and neurological regulation, resulting in a higher incidence of overactive bladder. This increased prevalence among older adults leads to a greater need for effective management options. Consequently, there is a rising demand for various treatment modalities, including pharmacological therapies, neuromodulation techniques, and minimally invasive surgical procedures, which collectively contribute to the overall growth of the market by addressing the needs of this demographic.

Restraints in the Global Overactive Bladder Treatment Market

The Global Overactive Bladder Treatment market faces significant challenges due to the adverse effects associated with various treatment options, especially anticholinergics. Common side effects, including dry mouth, constipation, and cognitive impairment, particularly among elderly patients, can lead to decreased patient adherence to prescribed therapies. This dissatisfaction often results in patients discontinuing their treatment, thereby hindering market expansion. Consequently, there is a growing demand for safer alternatives, such as B3-adrenergic agonists or minimally invasive approaches, to address these issues while improving patient outcomes and satisfaction in managing overactive bladder symptoms.

Market Trends of the Global Overactive Bladder Treatment Market

The global overactive bladder treatment market is witnessing a significant trend towards the rising adoption of neuromodulation therapies, notably tibial and sacral nerve stimulation. These minimally invasive, device-based interventions are favored for their capacity to deliver lasting symptom relief while presenting fewer adverse effects compared to traditional pharmacological options. As awareness among patients and healthcare providers continues to grow, alongside promising clinical outcomes, there is a marked increase in the preference for these innovative treatments. This shift not only enhances patient quality of life but also propels the overall expansion of the overactive bladder treatment market on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Overactive Bladder Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Anticholinergics
• Beta-3 Adrenergic Agonists
• Neuromodulation
• Botulinum Toxin Injections
• Behavioral Therapies

Global Overactive Bladder Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravesical
• Transdermal
• Injectable

Global Overactive Bladder Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Overactive Bladder Treatment Market Size & CAGR (2025-2032)

• North America (Treatment Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axonics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyorin Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations